CA2724830A1 - Inhibition of the nt-3:trkc bound and its application to the treatment of cancer such as neuroblastoma - Google Patents

Inhibition of the nt-3:trkc bound and its application to the treatment of cancer such as neuroblastoma Download PDF

Info

Publication number
CA2724830A1
CA2724830A1 CA2724830A CA2724830A CA2724830A1 CA 2724830 A1 CA2724830 A1 CA 2724830A1 CA 2724830 A CA2724830 A CA 2724830A CA 2724830 A CA2724830 A CA 2724830A CA 2724830 A1 CA2724830 A1 CA 2724830A1
Authority
CA
Canada
Prior art keywords
trkc
neurotrophin
cancer
trkc receptor
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2724830A
Other languages
English (en)
French (fr)
Inventor
Patrick Etienne Roger Mehlen
Servane Marie Severine Tauszig-Delamasure
Celine Jacqueline Andree Delloye
Jimena Bouzas-Rodriguez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Ecole Normale Superieure de Lyon
Centre Leon Berard
Universite Claude Bernard Lyon 1
Original Assignee
Centre National de la Recherche Scientifique CNRS
Ecole Normale Superieure de Lyon
Centre Leon Berard
Universite Claude Bernard Lyon 1
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Ecole Normale Superieure de Lyon, Centre Leon Berard, Universite Claude Bernard Lyon 1 filed Critical Centre National de la Recherche Scientifique CNRS
Publication of CA2724830A1 publication Critical patent/CA2724830A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/48—Nerve growth factor [NGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
CA2724830A 2008-05-21 2009-05-22 Inhibition of the nt-3:trkc bound and its application to the treatment of cancer such as neuroblastoma Abandoned CA2724830A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5505208P 2008-05-21 2008-05-21
US61/055.052 2008-05-21
PCT/EP2009/056253 WO2009141441A1 (en) 2008-05-21 2009-05-22 Inhibition of the nt-3:trkc bound and its application to the treatment of cancer such as neuroblastoma

Publications (1)

Publication Number Publication Date
CA2724830A1 true CA2724830A1 (en) 2009-11-26

Family

ID=40941707

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2724830A Abandoned CA2724830A1 (en) 2008-05-21 2009-05-22 Inhibition of the nt-3:trkc bound and its application to the treatment of cancer such as neuroblastoma

Country Status (5)

Country Link
US (2) US20110229485A1 (https=)
EP (1) EP2294416A1 (https=)
JP (2) JP5758289B2 (https=)
CA (1) CA2724830A1 (https=)
WO (1) WO2009141441A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6929231B2 (ja) * 2015-05-29 2021-09-01 イグナイタ インコーポレイテッド Ｒｔｋ突然変異細胞を有する患者を処置するための組成物及び方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5348856A (en) * 1991-07-08 1994-09-20 E. R. Squibb & Sons, Inc. DNA encoding TRKC protein
US5789187A (en) * 1992-08-27 1998-08-04 Worcester Foundation For Experimental Biology Identification of differentiation factor receptors which inhibit the tumorigenicity of neuroblastoma cells in a ligand-independent manner
US20040058416A1 (en) * 1994-03-18 2004-03-25 Presta Leonard G. Human trk receptors and neurotrophic factor inhibitors
US6008003A (en) * 1997-10-28 1999-12-28 Promega Corporation Non-invasive diagnostic method for interstitial cystitis and bladder cancer
WO1999040103A1 (en) * 1998-02-10 1999-08-12 The Children's Medical Center Corporation Nt-3 and medulloblastoma
US6548062B2 (en) * 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
ATE446366T1 (de) * 2000-06-22 2009-11-15 Genentech Inc Agonistische monoklonale antikörper gegen trkc
JP2003231687A (ja) * 2002-02-04 2003-08-19 Japan Tobacco Inc ピラゾリル縮合環化合物及びその医薬用途
CN101218229A (zh) * 2005-05-05 2008-07-09 阿斯利康(瑞典)有限公司 吡唑基-氨基取代的嘧啶及其在癌症治疗中的应用
WO2007099133A1 (en) * 2006-02-28 2007-09-07 Centre National De La Recherche Scientifique (Cnrs) Screening for anti-cancer compounds using netrin-1 activity
WO2008045627A2 (en) * 2006-10-06 2008-04-17 Irm Llc Protein kinase inhibitors and methods for using thereof

Also Published As

Publication number Publication date
JP2011524516A (ja) 2011-09-01
JP2015092170A (ja) 2015-05-14
US20140186364A1 (en) 2014-07-03
WO2009141441A1 (en) 2009-11-26
US20110229485A1 (en) 2011-09-22
JP5758289B2 (ja) 2015-08-05
EP2294416A1 (en) 2011-03-16

Similar Documents

Publication Publication Date Title
US8309524B2 (en) Chimeric RGMa polypeptides
EP2081586B1 (en) Rspondins as modulators of angiogenesis and vasculogenesis
Bouzas-Rodriguez et al. Neurotrophin-3 production promotes human neuroblastoma cell survival by inhibiting TrkC-induced apoptosis
Willis et al. Chronic inflammatory pain and the neurovascular unit: a central role for glia in maintaining BBB integrity?
JP2017505428A (ja) 診断及び治療の方法
ES2423182T3 (es) Variantes de unión CD44 en las enfermedades neurodegenerativas
Ma et al. Enhancing Gpx1 palmitoylation to inhibit angiogenesis by targeting PPT1
Zhou et al. EphA4/EphrinB2 signaling mediates pericyte-induced transient glia limitans formation as a secondary protective barrier after subarachnoid hemorrhage in mice
WO2009141440A1 (en) Netrin-1 overexpression as a biological marker and a survival factor for aggressive neuroblastoma
JP7025034B2 (ja) 膵臓炎、腎損傷および腎臓癌を治療および予防するための組成物および方法
US20060241284A1 (en) Transmembrane protein amigo and uses thereof
US20060121465A1 (en) Sgk and nedd used as diagnostic and therapeutic targets
CA2793750A1 (en) Method and compositions to induce apoptosis of tumoral cells expressing shh
US20140186364A1 (en) Inhibition of the nt-3:trkc bound and its application to the treatment of cancer such as neuroblastoma
WO2022152715A1 (en) Inhibitors of trpm3 and their uses
KR102601020B1 (ko) 파골 세포 분화 조절용 조성물 및 이의 용도
WO2006020755A2 (en) Methods for identifying inhibitors of the mtor pathway as diabetes therapeutics
Mei et al. Neuroprotection of botch in experimental intracerebral hemorrhage in rats
JP4503287B2 (ja) 星状細胞及び星状細胞性腫瘍細胞の増殖を阻害する方法と、ニューロンの生存を高める方法、並びにその使用
US20130011404A1 (en) Methods and Compositions for Regulating Musashi Function
JP2009515832A (ja) 神経変性疾患の治療のためのミュラー管抑制物質（ｍｉｓ）受容体のモジュレーション方法
US7879568B2 (en) Method for the diagnosis and prognosis of demyelinating diseases
KR20260052271A (ko) 나트륨 누출 통로인 nalcn 및 고혈압의 상관관계 및 이를 이용한 고혈압 진단 또는 치료용 조성물
WO2002046466A2 (en) Complexes of brca and stat polypeptides and methods of use in the detection and treatment of cancer
TWI328613B (en) Neurodegenerative disease treatment

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140516

FZDE Discontinued

Effective date: 20180525